A randomised controlled implementation trial of the feasibility and effectiveness of school staff delivery of a selective substance use and mental health program during the COVID-19 pandemic.

Publication date: Jan 28, 2025

Preventure is a selective school-based personality-targeted program that has shown long-term benefits in preventing student alcohol use, internalising and externalising problems when delivered by psychologists. In this first Australian randomised controlled trial of school staff implementation of Preventure, we aimed to examine i) acceptability, feasibility, and fidelity and ii) effectiveness of Preventure on student alcohol use, internalising, and externalising symptoms. A cluster-randomised controlled implementation trial was conducted in Sydney, Australia and was guided by the RE-AIM framework (Glasgow et al. 1999); which measures reach, effectiveness, adoption, implementation, and maintenance. Schools were randomly assigned to either the Preventure intervention or active control (health education as usual). Nominated school staff from intervention schools received training and delivered the program to students with elevated scores on one of four personality types targeted in the program. School staff completed surveys on RE-AIM measures, which were analysed using descriptive statistics and thematic analysis. Students completed surveys at baseline and six months post-intervention; mixed-effects regression examined intervention by time interactions on alcohol use, internalising and externalising problems, at six-month follow-up. The study was prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12620000790943, registration date 6 August 2020). 553 students across 8 schools participated in the baseline survey. Of these, 40% had elevated scores on one of the four personality profiles, resulting in 220 students in the current study (102 students in intervention schools, 118 students in control schools; mean age 13. 6, 45. 7% female). Most RE-AIM domains showed high ratings, with school staff showing good adherence and confidence in delivery. However, teachers reported difficulties with feasibility, particularly a lack of time. Student outcomes: There were significant improvements in depression and conduct problems across both intervention and control across time. There were no significant main or interaction effects of the intervention on student alcohol use, internalising, or externalising problems. Teachers and students rated the program highly. However, concerns around feasibility may limit teacher-led application of the program in the Australian context. Alternative approaches, such as delivery by dedicated personnel within schools without a teaching load, may be critical in implementing such evidence-based interventions at scale. The study was prospectively registered with the Australian New Zealand Clinical Trials Registry, registration number: ACTRN12620000790943, registration date: 6 August 2020.

Open Access PDF

Concepts Keywords
Actrn12620000790943 Adolescent
August Alcohol use
Australia Australia
Pandemic Child
Psychologists COVID-19
Feasibility Studies
Female
Humans
Implementation
Male
Mental health
New South Wales
Personality
Prevention
Program Evaluation
Randomised controlled trial
School
School Health Services
School Teachers
Schools
Selective
Students
Substance-Related Disorders

Semantics

Type Source Name
drug DRUGBANK Etoperidone
disease MESH substance use
disease MESH COVID-19 pandemic
drug DRUGBANK Ethanol
disease IDO intervention
disease MESH depression
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease MESH mental disorders
disease IDO symptom
disease MESH comorbidity
disease MESH anxiety
disease MESH conduct disorder
disease MESH impulsivity
disease MESH suicidal ideation
drug DRUGBANK Spinosad
disease IDO process
drug DRUGBANK Trestolone
drug DRUGBANK Ademetionine
drug DRUGBANK Methionine
disease MESH Anxiety Disorder
drug DRUGBANK Hyaluronic acid
drug DRUGBANK Iron
disease MESH uncertainty
disease MESH infection
disease MESH burnout
drug DRUGBANK Adenosine
disease IDO role
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Behavioral Problems
disease MESH Alcoholism
pathway KEGG Alcoholism
disease MESH major depressive disorder
drug DRUGBANK Ranitidine
drug DRUGBANK Sulfasalazine

Original Article

(Visited 1 times, 1 visits today)